Eaton Vance Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Eaton Vance Management’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-2,019	Closed	-$151K	–	2063
2021 Q4	$151K	Sell	2,019 -1,111	-35%	-$87.2K	﹤0.01%	1661
2021 Q3	$118K	Buy	3,130 +231	+8%	+$11.4K	﹤0.01%	1406
2021 Q2	$127K	Buy	2,899 +568	+24%	+$27.8K	﹤0.01%	1791
2021 Q1	$115K	Buy	+2,331	New	+$116K	﹤0.01%	1572
2018 Q3	–	Sell	-2,040	Closed	-$236K	–	1198
2018 Q2	$236K	Buy	+2,040	New	+$204K	﹤0.01%	1134

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Eaton Vance Management's ENTA Position: Q1 2022 in Review

Eaton Vance Management sold out of Enanta Pharmaceuticals (ENTA) in Q1 2022, closing a stake of 2,019 shares — an estimated $151K sold.

Eaton Vance Management first reported a position in ENTA in Q2 2018 and held it in 5 quarters. The position peaked at $236K in Q2 2018. 169 funds tracked by Wall St. Rank hold ENTA as of Q1 2022.

Eaton Vance Management reported no remaining Enanta Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Eaton Vance Management sold 2,019 Enanta Pharmaceuticals shares in Q1 2022, an estimated $151K.
Eaton Vance Management first reported a position in Enanta Pharmaceuticals in Q2 2018 and held it in 5 quarters.
Eaton Vance Management's Enanta Pharmaceuticals position peaked at $236K in Q2 2018.
169 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2022.

Based on Eaton Vance Management's 13F filing for Q1 2022, filed 16 May 2022.